perazine perazine perazine (taxilan) is a moderate-potency typical antipsychotic of the phenothiazine class. it is quite similar to chlorpromazine, and acts as a dopamine antagonist. a 2014 systematic review compared it with other antipsychotic drugs: perazine versus other antipsychotic drugs for schizophrenia summary the number, size and reporting of randomized controlled perazine trials are insufficient to present firm conclusions about the properties of this antipsychotic. it is possible that perazine is associated with a similar risk of extrapyramidal side effects as some atypical antipsychotics but this is based on few comparisons of limited power. outcome findings in words findings in numbers quality of evidence global state no better or deteriorationfollow-up: average 5 weeksperazine may decrease the chance of experiencing this outcome. these findings are based on data of low quality.rr 0.43 (0.23 to 0.81)low mental state less than 30% bprs reductionfollow-up: mean 5 weeksthe average overall mental state score in the perazine group was lower than for those given other antipsychotic drugs but the difference between the groups was not clear. these findings are based on data of low quality.rr 0.82 (0.61 to 1.09)low adverse effects needing antiparkinson medicationfollow-up: average 5 weeksperazine might increase the risk of experiencing this outcome but at present it is not possible to be confident about the difference between perazine and other antipsychotic drugs. data supporting this finding are very limited.rr 4.5 (1.04 to 19.45)very low leaving the study early - due to adverse eventsfollow-up: average 4 weeksthere was not a clear difference between perazine and the other antipsychotic drugs for this general outcome reflecting overall adverse event 'load'. these findings are based on data of low quality.0.87 (0.4 to 1.9)low acceptability of treatment leaving the studies early - any reasonfollow-up: 5 weeksperazine and the comparison antipsychotic drugs were equally tolerated. these findings are based on data of low quality.rr 0.62 (0.35 to 1.1)low no study reported any data on outcomes such as quality of life or information relating to satisfaction with care. perazineclinical dataahfs/drugs.cominternational drug namesatc coden05ab10 (who) identifiers iupac name 10--10h-phenothiazine cas number84-97-9 ypubchem cid4744drugbankdb12710 ychemspider4582 nunii8915147a2bkeggc16903chebichebi:59118 nchemblchembl1697766comptox dashboard (epa)dtxsid6048628 echa infocard100.001.435 chemical and physical dataformulac20h25n3smolar mass339.50 g·mol−13d model (jsmol)interactive image smiles cn1ccn(cc1)cccn2c3=cc=cc=c3sc4=cc=cc=c42 inchi inchi=1s/c20h25n3s/c1-21-13-15-22(16-14-21)11-6-12-23-17-7-2-4-9-19(17)24-20-10-5-3-8-18(20)23/h2-5,7-10h,6,11-16h2,1h3 nkey:weyvcqfugfrxom-uhfffaoysa-n n ny (what is this?) (verify) synthesis perazine synthesis: patents: alternate source: phenothiazine-10-propionitrile (1) is treated with a mixture of acid and alcohol giving methyl phenothiazinepropionate, cid:368244 (2). heating with 1-methylpiperazine (3) gives the amide (4). reduction of this last by means of diborane yields perazine (5).